Tirzepatide
A long-acting, synthetic dual agonist of the GLP-1 and GIP receptors, used clinically for type 2 diabetes and obesity.
Tag
Obesity
Pages related to Obesity.
A dose-linked mental health signal for semaglutide
A large EHR-based preprint links semaglutide to lower rates of many neuropsychiatric diagnoses, with a ‘legacy’ signal that tracks maximum achieved dose more than weight loss.
GLP‑1 use before burns linked to lower mortality
A large matched TriNetX study found prior GLP‑1 receptor agonist exposure was associated with fewer infections, less ICU care, and lower mortality after smaller thermal burns, but it cannot prove cause and effect.
A new look at GLP‑1s and suicidality risk
A large register study using two comparator cohorts plus a self-controlled design found no increased rate of suicide or suicide attempts after starting GLP‑1 receptor agonists.
Amylin may shape anxiety and sociability, differently by sex
A rat study links the pancreatic hormone amylin to anxiety-like behavior, aggression, and sociability, with the central amygdala driving some effects in opposite directions in males and females.
GLP-1 drugs and depression: a meta-analysis finds a signal, but the heterogeneity is huge
An open-access meta-analysis reports higher odds of depression-related adverse events among GLP-1 receptor agonist users (OR 1.49), but between-study heterogeneity is extreme (I² ~99%), which limits how literally the pooled number should be taken.
SURPASS-CVOT post hoc: broader cardiorenal outcomes favor tirzepatide vs dulaglutide
A post hoc analysis of SURPASS-CVOT expands the endpoint list beyond classic MACE. In patients with type 2 diabetes and established CVD, tirzepatide was associated with fewer composite cardiovascular + kidney events than dulaglutide, with more GI side effects.
Pancreatitis fears and GLP‑1s: the cleanest data so far
A living meta-analysis of placebo-controlled RCTs of semaglutide and tirzepatide lands near ‘no signal’ for acute pancreatitis. That’s reassuring, but rare-event uncertainty is exactly why this concern keeps coming back.
Surgery still outperforms GLP‑1 drugs over longer follow-up
A meta-analysis comparing bariatric surgery with GLP‑1 drugs found the gap widened as follow-up got longer. The signal is strong, but still confounded by non-random treatment selection and real-world access differences.